CDC - Cases, Deaths, & Testing. Available at: https://covid.cdc.gov/covid-data tracker/#cases_casesper100klast7days. Accessed February 25, 2022.

CDC – COVID Data Tracker

COVID-19 vaccinations in the United States.

() ()Guan W jie hua Liang W. Zhao Y. et al.

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.

Eur Respir J. 55: 2000547Wang D. Hu B. Hu C. et al.

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in wuhan, China.

JAMA. 323: 1061-1069Zhou F. Yu T. Du R. et al.

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Lancet. 395: 1054-1062Richardson S. Hirsch J.S. Narasimhan M. et al.

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area.

JAMA. 323: 2052-2059Bhatt A.S. Jering K.S. Vaduganathan M. et al.

Clinical outcomes in patients with heart failure hospitalized with COVID-19.

JACC Heart Fail. 9: 65-73Thygesen K. Alpert J.S. Jaffe A.S. et al.

Fourth universal definition of myocardial infarction (2018).

J Am Coll Cardiol. 72: 2231-2264Guo T. Fan Y. Chen M. et al.

Cardiovascular Implications of fatal outcomes of patients with Coronavirus disease 2019 (COVID-19).

JAMA Cardiol. 5: 1-8Shi S. Qin M. Shen B. et al.

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China.

JAMA Cardiol. 5: 802-810Du R.H. Liang L.R. Yang C.Q. et al.

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study.

Eur Respir J. 55: 2000524Bavishi C. Bonow R.O. Trivedi V. et al.

Acute myocardial injury in patients hospitalized with COVID-19 infection: a review.

Prog Cardiovasc Dis. 63: 682-689Sandoval Y. Januzzi J.L. Jaffe A.S.

Cardiac troponin for the diagnosis and risk-stratification of myocardial injury in COVID-19: JACC review topic of the week.

J Am Coll Cardiol. 76: 1244-1258Filippo O.D. D’Ascenzo F. Angelini F. et al.

Reduced rate of hospital admissions for ACS during Covid-19 outbreak in northern Italy.

N Engl J Med. 383Helal A. Shahin L. Abdelsalam M. et al.

Global effect of COVID-19 pandemic on the rate of acute coronary syndrome admissions: a comprehensive review of published literature.

Open Heart. 8: e001645Lai P.H. Lancet E.A. Weiden M.D. et al.

Characteristics associated with out-of-hospital cardiac arrests and resuscitations during the novel Coronavirus disease 2019 pandemic in New York City.

JAMA Cardiol. 5: 1154-1163Garcia S. Dehghani P. Grines C. et al.

Initial findings from the North American COVID-19 myocardial infarction registry.

J Am Coll Cardiol. 77: 1994-2003Wang N. Zhang M. Su H. et al.

Fibrinolysis is a reasonable alternative for STEMI care during the COVID-19 pandemic.

J Int Med Res. 48https://doi.org/10.1177/0300060520966151Daniels M.J. Cohen M.G. Bavry A.A. et al.

Reperfusion of ST-segment–elevation myocardial infarction in the COVID-19 era.

Circulation. 141: 1948-1950Saad M. Kennedy K.F. Imran H. et al.

Association between COVID-19 diagnosis and in-hospital mortality in patients hospitalized with ST-segment elevation myocardial infarction.

JAMA. 326: 1940-1952Xiang D. Xiang X. Zhang W. et al.

Management and outcomes of patients with STEMI during the COVID-19 pandemic in China.

J Am Coll Cardiol. 76: 1318-1324

Mechanisms of thrombosis and cardiovascular complications in COVID-19.

Thromb Res. 200: 1-8

COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation.

Clin Appl Thromb Hemost. 26https://doi.org/10.1177/1076029620938149Goshua G. Pine A.B. Meizlish M.L. et al.

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.

Lancet Haematol. 7: e575-e582Guan W.J. Ni Z.Y. Hu Y. et al.

Clinical characteristics of Coronavirus disease 2019 in China.

N Engl J Med. 382Fournier M. Faille D. Dossier A. et al.

Arterial thrombotic events in adult inpatients with COVID-19.

Mayo Clin Proc. 96: 295-303Bilaloglu S. Aphinyanaphongs Y. Jones S. et al.

Thrombosis in hospitalized patients with COVID-19 in a New York City health system.

JAMA. 324: 799-801Middeldorp S. Coppens M. Haaps TF van et al.

Incidence of venous thromboembolism in hospitalized patients with COVID-19.

J Thromb Haemost. 18: 1995-2002Roubinian N.H. Dusendang J.R. Mark D.G. et al.

Incidence of 30-day venous thromboembolism in adults tested for SARS-CoV-2 infection in an integrated health care system in Northern California.

JAMA Intern Med. 181: 997-1000Lodigiani C. Iapichino G. Carenzo L. et al.

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy.

Thromb Res. 191: 9-14Klok F.A. Kruip M.J.H.A. van der Meer N.J.M. et al.

Incidence of thrombotic complications in critically ill ICU patients with COVID-19.

Thromb Res. 191: 145-147Jimenez D. Garcia-Sanchez A. Rali P. et al.

Incidence of VTE and bleeding among hospitalized patients with Coronavirus disease 2019: a systematic review and meta-analysis.

Chest. 159: 1182-1196Helms J. Tacquard C. Severac F. et al.

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.

Intensive Care Med. 46: 1089-1098Barry O de Mekki A. Diffre C. et al.

Arterial and venous abdominal thrombosis in a 79-year-old woman with COVID-19 pneumonia.

Radiol Case Rep. 15: 1054-1057Shah A. Donovan K. McHugh A. et al.

Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study.

Crit Care. 24: 561Oxley T.J. Mocco J. Majidi S. et al.

Large-vessel stroke as a presenting feature of Covid-19 in the young.

N Engl J Med. 382: e60Choudry F.A. Hamshere S.M. Rathod K.S. et al.

High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction.

J Am Coll Cardiol. 76: 1168-1176Bellosta R. Luzzani L. Natalini G. et al.

Acute limb ischemia in patients with COVID-19 pneumonia.

J Vasc Surg. 72: 1864-1872Merkler A.E. Parikh N.S. Mir S. et al.

Risk of ischemic stroke in patients with Coronavirus disease 2019 (COVID-19) vs patients with influenza.

JAMA Neurol. 77: 1366-1372https://doi.org/10.1001/jamaneurol.2020.2730Qureshi A.I. Baskett W.I. Huang W. et al.

Acute ischemic stroke and COVID-19.

Stroke. 52: 905-912Frankfurter C. Buchan T.A. Kobulnik J. et al.

Reduced rate of hospital presentations for heart failure during the Covid-19 pandemic in Toronto, Canada.

Can J Cardiol. 36: 1680-1684Cox Z.L. Lai P. Lindenfeld J.

Decreases in acute heart failure hospitalizations during COVID-19.

Eur J Heart Fail. 22: 1045-1046Petrilli C.M. Jones S.A. Yang J. et al.

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study.

BMJ. 369: m1966Alvarez-Garcia J. Lee S. Gupta A. et al.

Prognostic impact of prior heart failure in patients hospitalized with COVID-19.

J Am Coll Cardiol. 76: 2334-2348Yonas E. Alwi I. Pranata R. et al.

Effect of heart failure on the outcome of COVID-19 — a meta analysis and systematic review.

Am J Emerg Med. 46: 204-211Kindermann I. Barth C. Mahfoud F. et al.

Update on myocarditis.

J Am Coll Cardiol. 59: 779-792Kumar K. Guirgis M. Zieroth S. et al.

Influenza myocarditis and myositis: case presentation and review of the literature.

Can J Cardiol. 27: 514-522

Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus.

Ann Saudi Med. 36: 78-80Maisch B. Ristić A.D. Hufnagel G. et al.

Pathophysiology of viral myocarditis the role of humoral immune response.

Cardiovasc Pathol. 11: 112-122Kawakami R. Sakamoto A. Kawai K. et al.

Pathological evidence for SARS-CoV-2 as a cause of myocarditis.

J Am Coll Cardiol. 77: 314-325Rathore S.S. Rojas G.A. Sondhi M. et al.

Myocarditis associated with Covid-19 disease: a systematic review of published case reports and case series.

Int J Clin Pract. 75: e14470Boehmer T.K. Kompaniyets L. Lavery A.M. et al.

Association between COVID-19 and myocarditis using hospital-based administrative data - United States, March 2020-January 2021.

MMWR Morb Mortal Wkly Rep. 70: 1228-1232Sawalha K. Abozenah M. Kadado A.J. et al.

Systematic review of COVID-19 related myocarditis: insights on management and outcome.

Cardiovasc Revasc Med. 23: 107-113Mele D. Flamigni F. Rapezzi C. et al.

Myocarditis in COVID-19 patients: current problems.

Intern Emerg Med. 16: 1123-1129Shah R.M. Shah M. Shah S. et al.

Takotsubo syndrome and COVID-19: associations and implications.

Curr Probl Cardiol. 46: 100763

Stress-induced cardiomyopathy—considerations for diagnosis and management during the COVID-19 pandemic.

Medicina. 58: 192Liu K. Fang Y.Y. Deng Y. et al.

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province.

Chin Med J (Engl). 133: 1025-1031Cho J.H. Namazi A. Shelton R. et al.

Cardiac arrhythmias in hospitalized patients with COVID-19: a prospective observational study in the western United States.

PLoS One. 15: e0244533Bhatla A. Mayer M.M. Adusumalli S. et al.

COVID-19 and cardiac arrhythmias.

Heart Rhythm. 17: 1439-1444DeLago A.J. Essa M. Ghajar A. et al.

Incidence and mortality trends of atrial fibrillation/atrial flutter in the United States 1990 to 2017.

Am J Cardiol. 148: 78-83Chen M.Y. Xiao F.P. Kuai L. et al.

Outcomes of atrial fibrillation in patients with COVID-19 pneumonia: a systematic review and meta-analysis.

Am J Emerg Med. 50: 661-669Harrison S.L. Fazio-Eynullayeva E. Lane D.A. et al.

Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults ≥ 50 years with COVID-19.

J Arrhythm. 37: 231-237Li Z. Shao W. Zhang J. et al.

Prevalence of atrial fibrillation and associated mortality among hospitalized patients with COVID-19: a systematic review and meta-analysis.

Front Cardiovasc Med. 8: 720129Louis D. Kennedy K. Saad M. et al.

Pre-admission oral anticoagulation is associated with fewer thrombotic comlpications in patients admitted with COVID-19.

J Am Coll Cardiol. 79: 1798Rosenberg E.S. Dufort E.M. Udo T. et al.

Association of Treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State.

JAMA. 323: 2493-2502Cavalcanti A.B. Zampieri F.G. Rosa R.G. et al.

Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19.

N Engl J Med. 383: 2041-2052Patel Y.R. Louis D.W. Atalay M. et al.

Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series.

J Cardiovasc Magn Reson. 23: 101Shaw K.E. Cavalcante J.L. Han B.K. et al.

Possible association between COVID-19 vaccine and myocarditis: clinical and CMR findings.

JACC Cardiovasc Imaging. 14: 1856-1861Witberg G. Barda N. Hoss S. et al.

Myocarditis after Covid-19 vaccination in a large health care organization.

N Engl J Med. 385Oster M.E. Shay D.K. Su J.R. et al.

Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021.

JAMA. 327: 331-340Kammen MS van Sousa DA de Poli S. et al.

Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2 vaccine–induced immune thrombotic thrombocytopenia.

JAMA Neurol. 78: 1314-1323Cari L. Alhosseini M.N. Fiore P. et al.

Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data.

J Autoimmun. 125: 102742Patone M. Mei X.W. Handunnetthi L. et al.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.

Nat Med. : 1-13https://doi.org/10.1038/s41591-021-01630-0Xie Y. Xu E. Bowe B. et al.

Long-term cardiovascular outcomes of COVID-19.

Nat Med. : 1-8https://doi.org/10.1038/s41591-022-01689-3Crook H. Raza S. Nowell J. et al.

Long covid—mechanisms, risk factors, and management.

BMJ. 374: n1648Leong D.P. Banerjee A. Yusuf S.

COVID-19 vaccination prioritization on the basis of cardiovascular risk factors and number needed to vaccinate to prevent death.

Can J Cardiol. 37: 1112-1116